Neovascular Age-Related Macular Degeneration (nAMD): A Review of Emerging Treatment Options

References

• World Health Organization. World report on vision; 2019. Available from: https://www.who.int/publications/i/item/9789241516570. Accessed February 20, 2022.
   Google Scholar
• Miller JW, Le Couter J, Strauss EC, Ferrara N. Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology. 2013;120(1):106–114. doi:10.1016/j.ophtha.2012.07.038
   PubMed Web of Science ®Google Scholar
• Okamoto N, Tobe T, Hackett SF, et al. Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am J Pathol. 1997;151(1):281.
   PubMed Web of Science ®Google Scholar
• Tobe T, Okamoto N, Vinores MA, et al. Evolution of neovascularization in mice with overexpression of vascular endothelial growth factor in photoreceptors. Invest Ophthalmol Vis Sci. 1998;39(1):180–188.
   PubMed Web of Science ®Google Scholar
• Schwesinger C, Yee C, Rohan RM, et al. Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium. Am J Pathol. 2001;158(3):1161–1172. doi:10.1016/S0002-9440(10)64063-1
   PubMed Web of Science ®Google Scholar
• Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, De Jong PTVM. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol. 1997;81(2):154–162. doi:10.1136/bjo.81.2.154
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431. doi:10.1056/NEJMoa054481
   PubMed Web of Science ®Google Scholar
• Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432–1444. doi:10.1056/NEJMoa062655
   PubMed Web of Science ®Google Scholar
• Group T of AMDWPT (TAP) S. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials—TAP report 1. Arch Ophthalmol. 1999;117(10):1329–1345. doi:10.1001/archopht.117.10.1329
   PubMedGoogle Scholar
• Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120(11):2292–2299. doi:10.1016/j.ophtha.2013.03.046
   PubMed Web of Science ®Google Scholar
• Singer MA, Awh CC, Sadda S, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2012;119(6):1175–1183. doi:10.1016/j.ophtha.2011.12.016
   PubMed Web of Science ®Google Scholar
• Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537–2548. doi:10.1016/j.ophtha.2012.09.006
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ. Intravitreal avastin: the low cost alternative to lucentis? Am J Ophthalmol. 2006;142(1):141–143. doi:10.1016/j.ajo.2006.03.036
   PubMed Web of Science ®Google Scholar
• Steinbrook R. The price of sight–ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med. 2006;355(14):1409–1412. doi:10.1056/NEJMp068185
   PubMed Web of Science ®Google Scholar
• Martin DF, Ying G, Grunwald JE, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897–1908.
   PubMed Web of Science ®Google Scholar
• Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388–1398. doi:10.1016/j.ophtha.2012.03.053
   PubMed Web of Science ®Google Scholar
• Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013;382(9900):1258–1267. doi:10.1016/S0140-6736(13)61501-9
   PubMed Web of Science ®Google Scholar
• Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148(1). doi:10.1016/j.ajo.2009.01.024
   PubMed Web of Science ®Google Scholar
• Silva R, Berta A, Larsen M, Macfadden W, Feller C, Monés J. Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND Study. Ophthalmology. 2018;125(1):57–65. doi:10.1016/j.ophtha.2017.07.014
   PubMed Web of Science ®Google Scholar
• Ohji M, Takahashi K, Okada AA, et al. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR: a randomized controlled trial. Adv Ther. 2020;37(3):1173–1187. doi:10.1007/s12325-020-01236-x
   PubMed Web of Science ®Google Scholar
• Gaudreault J, Gunde T, Floyd HS, et al. Preclinical pharmacology and safety of ESBA1008, a single-chain antibody fragment, investigated as potential treatment for age related macular degeneration. Invest Ophthalmol Vis Sci. 2012;53(14):3025.
   Google Scholar
• Evans RN, Reeves BC, Maguire MG, et al. Associations of variation in retinal thickness with visual acuity and anatomic outcomes in eyes with neovascular age-related macular degeneration lesions treated with anti–vascular endothelial growth factor agents. JAMA Ophthalmol. 2020;138(10):1043. doi:10.1001/jamaophthalmol.2020.3001
   PubMed Web of Science ®Google Scholar
• Escher D, Schmidt A, Steiner P, Maurer P, Weissgerber G. Single-chain antibody fragments in ophthalmology; 2015. Available from: https://www.euretina.org/nice2015/programme/free-papers-details.asp?id=4072&day=0. Accessed November 28, 2021.
   Google Scholar
• Szabó E, Phillips DJ, Droste M, et al. Antitumor activity of DLX1008, an anti-VEGFA antibody fragment with low picomolar affinity, in human glioma models. J Pharmacol Exp Ther. 2018;365(2):422–429. doi:10.1124/jpet.117.246249
   PubMedGoogle Scholar
• Borras L, Gunde T, Tietz J, et al. Generic approach for the generation of stable humanized single-chain Fv fragments from rabbit monoclonal antibodies. J Biol Chem. 2010;285(12):9054. doi:10.1074/jbc.M109.072876
   PubMed Web of Science ®Google Scholar
• Dugel PU, Singh RP, Koh A, et al. HAWK and HARRIER: ninety-six-week outcomes from the Phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2021;128(1):89–99. doi:10.1016/j.ophtha.2020.06.028
   PubMed Web of Science ®Google Scholar
• Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127(1):72–84. doi:10.1016/j.ophtha.2019.04.017
   PubMed Web of Science ®Google Scholar
• Singer M, Albini TA, Seres A, et al. Clinical characteristics and outcomes of eyes with intraocular inflammation after brolucizumab: post hoc analysis of HAWK and HARRIER. Ophthalmol Retin. 2021;6(2):97–108. doi:10.1016/j.oret.2021.05.003
   PubMedGoogle Scholar
• ASRS Clinical Updates. Beovu update for ASRS members; 2021. Available from: https://www.asrs.org/members/login/960?returnUrl=%2Fclinical%2Fclinical-updates%2F960%2FBeovu-Update-for-ASRS-Member. Accessed November 28, 2021.
   Google Scholar
• Novartis. Brolucizumab Information. Available from: https://www.brolucizumab.info/. Accessed February 26, 2022.
   Google Scholar
• Mukai R, Matsumoto H, Akiyama H. Risk factors for emerging intraocular inflammation after intravitreal brolucizumab injection for age-related macular degeneration. PLoS One. 2021;16(12):e0259879. doi:10.1371/journal.pone.0259879
   PubMed Web of Science ®Google Scholar
• Regula JT, Lundh von leithner P, Foxton R, et al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med. 2016;8(11):1265–1288. doi:10.15252/emmm.201505889
   PubMed Web of Science ®Google Scholar
• Regula JT, Leithner PL, Von, Foxton R, et al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med. 2019;11(5):e10666. doi:10.15252/emmm.201910666
   PubMed Web of Science ®Google Scholar
• Sahni J, Dugel PU, Patel SS, et al. Safety and efficacy of different doses and regimens of faricimab vs ranibizumab in neovascular age-related macular degeneration: the AVENUE Phase 2 randomized clinical trial. JAMA Ophthalmol. 2020;138(9):955–963. doi:10.1001/jamaophthalmol.2020.2685
   PubMed Web of Science ®Google Scholar
• Saharinen P, Eklund L, Alitalo K. Therapeutic targeting of the angiopoietin–TIE pathway. Nat Rev Drug Discov. 2017;16(9):635–661.
   PubMed Web of Science ®Google Scholar
• Campochiaro PA. Molecular pathogenesis of retinal and choroidal vascular diseases. Prog Retin Eye Res. 2015;49:67–81. doi:10.1016/j.preteyeres.2015.06.002
   PubMed Web of Science ®Google Scholar
• Khanani AM, Patel SS, Ferrone PJ, et al. Efficacy of every four monthly and quarterly dosing of faricimab vs ranibizumab in neovascular age-related macular degeneration: the STAIRWAY Phase 2 randomized clinical trial. JAMA Ophthalmol. 2020;138(9):964–972. doi:10.1001/jamaophthalmol.2020.2699
   PubMed Web of Science ®Google Scholar
• Khanani AM, Heier J, Ruiz CQ, et al. Faricimab in neovascular age-related macular degeneration: 1-year efficacy, safety, and durability in the Phase 3 TENAYA and LUCERNE trials. Invest Ophthalmol Vis Sci. 2021;62(8):428.
   Google Scholar
• Plückthun A. Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy. Annu Rev Pharmacol Toxicol. 2015;55(1):489–511. doi:10.1146/annurev-pharmtox-010611-134654
   PubMed Web of Science ®Google Scholar
• Kunimoto D, Yoon YH, Wykoff CC, et al. Efficacy and safety of abicipar in neovascular age-related macular degeneration: 52-week results of Phase 3 randomized controlled study. Ophthalmology. 2020;127(10):1331–1344. doi:10.1016/j.ophtha.2020.03.035
   PubMed Web of Science ®Google Scholar
• Molecular Partners. Allergan and molecular partners announce topline safety results from MAPLE study of abicipar pegol; 2021. Available from: https://investors.molecularpartners.com/news-releases/news-release-details/allergan-and-molecular-partners-announce-topline-safety-results. Accessed November 28, 2021.
   Google Scholar
• Allergan. A study to evaluate abicipar pegol for safety and treatment effect in participants with neovascular age-related macular degeneration (AMD). Available from: http://clinicaltrials.gov/ct2/show/NCT03539549. Accessed November 28, 2021.
   Google Scholar
• Al-Khersan H, Hussain RM, Ciulla TA, Dugel PU. Innovative therapies for neovascular age-related macular degeneration. Expert Opin Pharmacother. 2019;20(15):1879–1891. doi:10.1080/14656566.2019.1636031
   PubMed Web of Science ®Google Scholar
• Hong L, Huang X, Ngo W, et al. KSI-301: an anti-VEGF antibody biopolymer conjugate with extended half-life for treatment of neovascular retinal diseases. Invest Ophthalmol Vis Sci. 2018;59(9):211.
   Web of Science ®Google Scholar
• Patel SS, Naor J, Qudrat A, et al. Phase 1 first-in-human study of KSI-301: a novel anti-VEGF antibody biopolymer conjugate with extended durability. Invest Ophthalmol Vis Sci. 2019;60(9):3670.
   Web of Science ®Google Scholar
• Kodiak Sciences Inc. A study to evaluate the efficacy and safety of KSI-301, an anti-VEGF antibody biopolymer conjugate, versus aflibercept in patients with neovascular (Wet) age-related macular degeneration. (DAZZLE). Available from: http://clinicaltrials.gov/ct2/show/NCT04049266. Accessed November 28, 2021.
   Google Scholar
• Kodiak. Third quarter 2020 R&D webinar; 2020. Available from: https://ir.kodiak.com/static-files/c59bbe11-0e07-4819-b063-fddd4dbc24e4/. Accessed November 28, 2021.
   Google Scholar
• Khanani AM, Callanan D, Dreyer R, et al. End-of-study results for the ladder phase 2 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmol Retin. 2021;5(8):775–787. doi:10.1016/j.oret.2020.11.004
   PubMedGoogle Scholar
• Holekamp NM, Campochiaro PA, Chang MA, et al. Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2021;129(3):295–307. doi:10.1016/j.ophtha.2021.09.016
   PubMed Web of Science ®Google Scholar
• Ocular Therapeutix, Inc. CLN-0046: treatment of AMD subjects with OTX-TKI. Available from: http://clinicaltrials.gov/ct2/show/NCT03630315. Accessed November 28, 2021.
   Google Scholar
• Wong JG, Chang A, Guymer RH, et al. Phase 1 study of an intravitreal axitinib hydrogel-based implant for the treatment of neovascular age-related macular degeneration (nAMD); 2021. Available from: https://ocutx.gcs-web.com/static-files/3c59d3b0-9995-4e63-a972-e233a7550b1b. Accessed November 28, 2021.
   Google Scholar
• Graybug. Our technologies and Pipeline; 2021. Available from: https://www.graybug.vision/our-technologies-and-pipeline/#gb102. Accessed November 28, 2021.
   Google Scholar
• Sharma A, Reddy P, Kuppermann BD, Bandello F, Lowenstein A. Biosimilars in ophthalmology: “Is there a big change on the horizon?”. Clin Ophthalmol. 2018;12:2137. doi:10.2147/OPTH.S180393
   PubMed Web of Science ®Google Scholar
• Sharma A, Kumar N, Kuppermann BD, Bandello F, Loewenstein A. Understanding biosimilars and its regulatory aspects across the globe: an ophthalmology perspective. Br J Ophthalmol. 2020;104(1):2–7. doi:10.1136/bjophthalmol-2019-314443
   PubMed Web of Science ®Google Scholar
• Samsung Bioepis. FDA approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab-nuna); 2021. Available from: https://www.samsungbioepis.com/en/newsroom/newsroomView.do?idx=254&currentPage=1. Accessed November 28, 2021.
   Google Scholar
• Bressler NM, Veith M, Hamouz J, et al. Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes. Br J Ophthalmol. 2021. 2021–319637. doi:10.1136/bjophthalmol-2021-319637
   Web of Science ®Google Scholar
• Holz FG, Oleksy P, Ricci F, Kaiser PK, Kiefer J, Schmitz-Valckenberg S. Efficacy and safety of biosimilar FYB201 compared with ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2021;129:54–63.
   PubMed Web of Science ®Google Scholar
• Ali RR. Ocular gene therapy: introduction to the special issue. Gene Ther. 2012;19(2):119–120.
   PubMed Web of Science ®Google Scholar
• Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18(5):358–378.
   PubMed Web of Science ®Google Scholar
• Auricchio A, Trapani I, Allikmets R. Gene therapy of ABCA4-associated diseases. Cold Spring Harb Perspect Med. 2015;5(5):a017301–a017301. doi:10.1101/cshperspect.a017301
   PubMed Web of Science ®Google Scholar
• Bordet T, Behar-Cohen F. Ocular gene therapies in clinical practice: viral vectors and nonviral alternatives. Drug Discov Today. 2019;24(8):1685–1693. doi:10.1016/j.drudis.2019.05.038
   PubMed Web of Science ®Google Scholar
• Liu Y, Fortmann SD, Shen J, et al. AAV8-antiVEGFfab ocular gene transfer for neovascular age-related macular degeneration. Mol Ther. 2018;26(2):542–549. doi:10.1016/j.ymthe.2017.12.002
   PubMed Web of Science ®Google Scholar
• Regenxbio Inc. Safety and tolerability of RGX-314 gene therapy for neovascular AMD trial. Available from: http://clinicaltrials.gov/ct2/show/NCT03066258. Accessed November 28, 2021.
   Google Scholar
• Ho A. Subretinal delivery of RGX-314 for neovascular AMD: end of Phase I/IIa study results; 2021. Available from: https://regenxbio.com/wp-content/uploads/2021/10/RGX-314_Ph1-2a_data_Allen-Ho_Retina_Society_Oct-2021.pdf. Accessed November 28, 2021.
   Google Scholar
• Regenxbio. News releases; 2021. Available from: https://regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-presents-positive-initial-data-phase-ii-aaviater-trial. Accessed November 28, 2021.
   Google Scholar
• Regenxbio. Wet AMDL; 2021. Available from: https://www.regenxbio.com/wet-amd/. Accessed November 28, 2021.
   Google Scholar
• Gelfman CM, Grishanin R, Bender KO, et al. Comprehensive preclinical assessment of ADVM-022, an intravitreal anti-VEGF gene therapy for the treatment of neovascular AMD and diabetic macular edema. J Ocul Pharmacol Ther. 2021;37(3):181–190. doi:10.1089/jop.2021.0001
   PubMed Web of Science ®Google Scholar
• Grishanin R, Vuillemenot B, Sharma P, et al. Preclinical evaluation of ADVM-022, a novel gene therapy approach to treating wet age-related macular degeneration. Mol Ther. 2019;27(1):118–129. doi:10.1016/j.ymthe.2018.11.003
   PubMed Web of Science ®Google Scholar
• Khanani A. ADVM-022 intravitreal gene therapy for neovascular AMD- phase 1 OPTIC study; 2021. Available from: https://adverum.com/wp-content/uploads/2021/10/OPTIC-Retina-Society-Meeting-Updated-9-30-2021a.pdf. Accessed November 28, 2021.
   Google Scholar